Cytotoxicity of Bendamustine, Alone and in Combination with Novel Agents, Toward Adult T-Cell Leukemia Cells
September 2024
in “
PLoS ONE
”
Studysummary This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation. Our plain-language summary of this paper — not a Tressless recommendation.
This study examines the cytotoxic effects of bendamustine (BDM) on adult T-cell leukemia (ATL) cells, both alone and in combination with novel agents such as tucidinostat, valemetostat, and ABT-737. The combination of BDM and tucidinostat showed promising results, enhancing cytotoxicity without significant hematological toxicity in a murine model and significantly slowing tumor growth in mice. The study suggests that this combination could potentially improve outcomes for patients with relapsed or refractory ATL, highlighting the need for further clinical trials to explore its efficacy and safety.
